ArticleAnnals of translational medicine2022
Clinical and resistance characterization of carbapenem-resistant
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Drug resistance mechanisms and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in pulmonary infections.BMC infectious diseases · 2026Article
- Development and Validation of a Nomogram for Predicting Mortality in Patients with Multidrug-Resistant Bacteria Infection: A Retrospective Cohort Study in China.International journal of general medicine · 2026Article
- Phenotypic and molecular characterization of Klebsiella pneumoniae in neonates and pediatric patients: antibiotic resistance, β-Lactamase genes, and sociodemographic risk factors.BMC infectious diseases · 2025Article
- Iron metabolism contributes to virulence by enhancing serum resistance in the emerging high-risk clone ST15 CRKP.Virulence · 2025Article
- Carbapenem-ResistantInfection prevention in practice · 2025Article
- Carbapenem-resistant Klebsiella pneumoniae gut colonization and subsequent infection in pediatric intensive care units in shanghai, China.Annals of clinical microbiology and antimicrobials · 2025Article
- New insights and perspectives on the virulence of hypervirulent Klebsiella pneumoniae.Folia microbiologica · 2025Review
- Molecular Characterization of Carbapenem and Colistin Resistance inMicroorganisms · 2024Article
- Carbapenemase-Producing Klebsiella pneumoniae Infections in Diabetic and Nondiabetic Hospitalized Patients.Cureus · 2024Article
- Clinical and Molecular Profile of Carbapenem ResistantInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: A total of 150 CRKP strains from Chongqing, Beijing, and Nantong, as well as the clinical data of the infected patients, were collected between 2019 and 2021. The carbapenemase phenotype was determined by CarbaNP test, and the outer membrane porin (OMP) genes ( Results: Patients infected with CRKP were mainly elderly, with comorbidity, and had undergone invasive operation and multiple antibiotic therapy. All strains exhibited high-level resistance to most antibiotics except for polymyxin B and tigecycline. Among the CRKP strains, 100 had the Conclusions: There were a few significant differences in the molecular epidemiology and clinical characteristics, but generally the features of CRKP from the three ICUs aligned fairly well, which might have resulted from dissemination through frequent personnel exchanges between regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.